IDEXX Labs Raises 2026 Guidance After Q2 Earnings Beat

IDEXX Laboratories (ISIN US45168D1046) reported second-quarter 2026 adjusted earnings per share of $4.27, surpassing the Wall Street consensus estimate of $3.96. Revenue reached $1.22 billion, a 10 percent year-over-year increase that exceeded analyst expectations of $1.20 billion. The company cited recurring diagnostics revenue growth of 10.3 percent and gross margin expansion to 64 percent as primary drivers of the outperformance.

Following the results, IDEXX management raised its full-year 2026 financial guidance. The revision reflects stronger productivity improvements and higher recurring revenue contributions. As of September 18, 2026, the stock trades at $506.48 on Nasdaq, near its 52-week low of $500.61 and roughly 25 percent below its 52-week high of $770.00.

Margin Expansion Drives Quarterly Performance

Gross margin improved to 64 percent in the second quarter, up from the prior year period. This expansion was supported by a mix shift toward higher-margin recurring revenue and operational productivity gains. The core animal health testing business remained the primary driver of top-line growth, with organic recurring diagnostics revenue increasing by 10.3 percent during the quarter.

The earnings beat of approximately $0.31 per share versus consensus provided a quantitative basis for the company's raised outlook. Investors are noting the combination of double-digit revenue growth and improved profitability as key factors supporting the current valuation despite the stock trading at a significant discount to recent highs.

Acquisition Expands Diagnostic Software Capabilities

IDEXX recently acquired CoVetAI Inc., a provider of AI-native ambient listening and clinical workflow software for veterinary practices. The deal supports the company's strategy of using software and artificial intelligence to enhance diagnostic insights and practice efficiency. Financial terms for the acquisition were not disclosed, but the move aims to strengthen the company's diagnostic ecosystem.

Additionally, IDEXX launched the Catalyst proBNP test, described as the first dual-species, in-clinic test for NT proBNP in its portfolio. This addition expands cardiac diagnostics capabilities across point-of-care and reference laboratory channels. These product and software developments provide qualitative support to the company's long-term growth strategy beyond immediate quarterly financial metrics.

Stifel Maintains Buy Rating and Target

Stifel reaffirmed its Buy rating on IDEXX Laboratories and maintained a price target of $675.00 following a survey of veterinary practices. As reported by GN stocks/earnings-beat, the current stock price of $506.48 represents a discount of roughly $168.52 to this target. The rating remains supported by the recent earnings beat and the company's raised guidance for 2026.